• Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies.

      Doria-Rose, Nicole A; Shen, Xiaoying; Schmidt, Stephen D; O'Dell, Sijy; McDanal, Charlene; Feng, Wenhong; Tong, Jin; Eaton, Amanda; Maglinao, Maha; Tang, Haili; et al. (Cold Spring Harbor Laboratory, 2021-12-15)
      The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in live virus and pseudovirus assays. Omicron was 41-84-fold less sensitive to neutralization than D614G and 5.3-7.4-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 µg mRNA-1273. A 50 µg boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.
    • Homologous and Heterologous Covid-19 Booster Vaccinations.

      Atmar, Robert L; Lyke, Kirsten E; Deming, Meagan E; Jackson, Lisa A; Branche, Angela R; El Sahly, Hana M; Rostad, Christina A; Martin, Judith M; Johnston, Christine; Rupp, Richard E; et al. (Massachusetts Medical Society, 2022-01-26)
      In this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.
    • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

      Gilbert, Peter B; Montefiori, David C; McDermott, Adrian B; Fong, Youyi; Benkeser, David; Deng, Weiping; Zhou, Honghong; Houchens, Christopher R; Martins, Karen; Jayashankar, Lakshmi; et al. (American Association for the Advancement of Science, 2021-11-23)
    • SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

      Pajon, Rolando; Doria-Rose, Nicole A; Shen, Xiaoying; Schmidt, Stephen D; O'Dell, Sijy; McDanal, Charlene; Feng, Wenhong; Tong, Jin; Eaton, Amanda; Maglinao, Maha; et al. (Massachusetts Medical Society, 2022-01-26)